logo
The 10-second fitness test you can do at home to predict your lifespan

The 10-second fitness test you can do at home to predict your lifespan

Daily Mail​20-06-2025
If you can't stand up without needing help, you're more likely to die in the next 10 years, a study suggests.
Researchers in Brazil gave over 4,000 adults a flexibility test to lower themselves on to the floor from a standing position and then get back up.
They were asked to do so with as little assistance as possible, such as using their hands, furniture or other people around them for balance.
Participants were then scored on a scale of zero to five for both sitting down and standing up, starting with five points and then losing one for each type of support needed.
The team found people who needed no help to sit down or stand up were six times less likely to die of heart disease or other cardiac issues within the next decade than those who wobbled or had more trouble.
And each one-point decline in score was associated with a one-third greater chance of dying of heart disease or other natural causes like cancer.
The test may be a good approximation because muscle strength and flexibility are thought to lower blood pressure and resting heart rate and reduce full-body inflammation, which can lower the risk of heart disease.
Researchers said while other studies have used balance and flexibility tests to measure longevity, the new study is the first to measure 'muscle strength/power, flexibility, balance and body composition' all at once.
Claudio Gil Araujo, lead study author and research director at an exercise-medicine clinic in Rio de Janeiro, where the data was collected, told the Washington Post: 'What makes this test special is that it looks at all of them at once, which is why we think it can be such a strong predictor.'
The researchers looked at 4,282 adults in Brazil ages 46 to 75, two thirds of whom were men. The average age was 59.
After 12 years on average, 15.5 percent of participants died of natural causes. Of those, 35 percent died of cardiovascular disease, 28 percent of cancer and 11 percent of respiratory diseases like pneumonia.
At the outset of the research, each participant was asked to sit down from a standing position and then get back up after.
They started with five points for each test and lost one point for every level of support they needed. This could include using their knees, holding on to a chair or taking someone's hand.
Participants also lost half a point every time they lost their balance or seemed unsteady.
Researchers then combined each person's sitting and standing scores to get the final result, with a maximum of 10.
People who scored zero to four points total had a six-fold increased chance of dying from cardiovascular disease than those who got a perfect 10.
Half of those who scored a zero on the test to get up off the floor died during the follow-up period compared to four percent of those who got a perfect score, an 11-fold difference.
Additionally, participants who scored between 4.5 and 7.5 were two to three times more likely to die in the next decade from heart disease or other natural causes.
Each one-point score decrease was associated with a 31 percent increased risk of cardiovascular death and 31 percent greater chance of death in the next decade from other natural causes.
The researchers also found after adjusting for factors like age, sex and body mass index (BMI), people with a history of coronary artery disease were three times more likely to die from natural causes compared to healthy participants.
There were several limitations to the study, however, including all of the participants being from a private clinic in Brazil, leading to a less diverse sample size. There was also no data on smoking status, a leading cause of death from heart disease and lung cancer.
To try the test for yourself, Dr Araujo suggests finding a partner to score you and steady you if you start to fall. People with joint issues should avoid trying it due to the risk of unnecessary injury.
Clear space around you but ensure there is a wall, chair or other support object nearby. Remove your shoes and socks and consider putting a pad down on bare floors.
Stand with your feet slightly apart and cross one foot in front of the other. Lower yourself until you are sitting on the ground and then stand back up, trying not to use support.
While there was a correlation between the scores and mortality, it is important to visit a doctor to get a full picture of health, as well as risk factors for different diseases.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Does semaglutide really contribute to vision loss?
Does semaglutide really contribute to vision loss?

Medical News Today

time4 hours ago

  • Medical News Today

Does semaglutide really contribute to vision loss?

As the popularity of GLP-1 medications used for weight loss continues to increase, more research is being done to further examine potential side effects of these medications. One such side effect is possible eye issues and vision loss, for which there is currently a great deal of conflicting studies link GLP-1 use to an increased risk for ocular diseases such as nonarteritic anterior ischemic optic neuropathy (NAION), diabetic retinopathy, papillitis, and optic nerve disorders. A new study reports that using semaglutide is not associated with an increased risk for eye disorders or diabetic this new study found a connection between semaglutide use and NAION, researchers say that the current evidence is insufficient to establish a definitive connection between the two. As the popularity of glucagon-like peptide-1 receptor agonists (GLP-1) used for the treatment of diabetes and in some cases for weight loss continues to increase, more research is being done to further examine potential side effects of these medications. One such side effect is possible eye issues and vision loss, for which there is currently a great deal of conflicting information. For example, a study published in July 2024 found participants taking semaglutide — the active ingredient found in Ozempic and Wegovy — were potentially at a higher risk of developing nonarteritic anterior ischemic optic neuropathy (NAION). Research published in February 2025 linked use of both semaglutide and tirzepatide — the active ingredient in Zepbound and Mounjaro — to not only an increased risk for NAION, but also papillitis and paracentral acute middle maculopathy. More recently, two studies published earlier this month showed similar findings. One study discovered that those taking semaglutide or tirzepatide may be at a higher risk of developing NAION than previously reported, as well as an increased risk of developing other optic nerve while the second study did not find a correlation between GLP-1 use and an increased risk for NAION, it did report a possible heightened chance for diabetic an additional study, also published this month in the journal JAMA Ophthalmology, reports that semaglutide is not associated with an increased risk for eye disorders or diabetic while the study did find a connection between semaglutide use and NAION, researchers say that the current evidence is insufficient to establish a definitive connection between the two. Why is there so much conflicting information on GLP-1s and eye issues? For those currently using or considering using GLP-1 medications, it can be confusing and frustrating to have multiple studies with differing — and sometimes conflicting — findings around a potential risk to eye health and vision. 'We've seen a couple of studies now that are coming out, especially because of how regularly these medications are being used now,' Benjamin Bert, MD, a board-certified ophthalmologist at MemorialCare Orange Coast Medical Center in Fountain Valley, CA — who was not involved in any of these studies — told Medical News Today.'And as expected, when we're talking about rare diseases, especially things like NAION, we do see some variability in the results that have been coming out,' added Bert.'Most of the research that's been published, including one of these two recent studies, does continue to support the idea that there is an increased risk of NAION occurring in patients that are taking these GLP-1 medications,' he continued.'It really just tells me that it's important, again, to go over all the risks and benefits with the patients of these different medications, and just let them know, hey, this is something new, we're still finding out about it, but there have been these reports of increasing the incidence,' Bert told us. 'We are seeing so many patients utilizing these drugs [that] we will see other complications during patient use that some would attribute to side effects of the medication,' David I. Geffen, OD, FAAO, director of optometric and refractive services at the Gordon Schanzlin New Vision Institute in La Jolla, CA, who was not involved in the research, explained to MNT. 'At this time early research in general shows the plus side of these medications outweighs some potential side effects.'Semaglutide not associated with diabetic retinopathy or eye disordersIn this most recent study, researchers conducted a systematic review of 78 clinical trials involving semaglutide use and ocular issues — including NAION, diabetic retinopathy, and eye disorders — encompassing more than 73,000 study participants. 'The risk of diabetic retinopathy came with the results of the SUSTAIN 6 trial, the first that compared the effect of semaglutide in cardiovascular outcomes in subjects with type 2 diabetes,' Fernando Gerchman, MD, PhD, professor of medicine in the Division of Endocrinology and Metabolism at the Hospital de Clínicas de Porto Alegre in Brazil and senior author of this study, told MNT. 'Observational data demonstrated a possible association between semaglutide and NAION,' Gerchman continued. 'This was replicated for others, but not in all studies published that look at this. We had the unique opportunity to meta-analyze with data derived from clinical trials. Our results confirmed these findings. However, there is some imprecision in our analyses and our findings need to be replicated.' Upon analysis, researchers found that semaglutide use was not associated with an increased risk for diabetic retinopathy or eye disorders. And although they did find a correlation between semaglutide use and NAION, scientists believe the evidence currently available is not enough to establish a definitive conclusion and more studies are needed.'These findings reassure [those] who prescribe semaglutide about the safety of doing that in diabetes and obesity,' Gerchman said. 'The risk of NAION needs to be taken into account and may help to decide about a more conservative approach in the definition of beginning semaglutide for those subjects without a clear indication for that.'Do I need to worry about my eyes when taking Ozempic? When looking at the results of these studies, Bert said it's important to note that when looking at the increases of percentages, it demonstrates that it is still very, very rare for a condition like NAION to occur.'[This study] reported in the control population that it was about 0.02% of the patients (with NAION), and in the treated group, the ones that were taking the GLP-1 medications, it went up to 0.04%,' he explained. 'So you could kind of sensationalize it and say, look, it doubled the risk for the patients to take the medication. But again, 0.02 to 0.04 is such a small amount that the overall risk is still very low.' Geffen commented that it is hard to tell a patient not to take GLP-1 medications unless they are already at high risk for NAION.'I feel the benefits for overall health make it a risk for the average person to take,' he continued. 'We need better studies developed for all the potential side effects of GLP-1 medications, not just eye related ones. So far these meds seem a godsend for many individuals.' For those considering starting GLP-1 medications, Bert advised talking to their physician and endocrinologist, and make sure to have an annual eye exam. 'It would be beneficial to have a baseline exam before you start the medication,' he explained. 'And then if you are high risk, of course, have another exam done shortly after starting just to make sure that you're not one of the people that fall into one of those categories where there can be worsening of the disease.' 'I think it's most important that these types of research projects continue to be done, and the benefit of having our electronic medical record systems, and we see in other countries that have kind of universal systems, you can do these very large population-based statistical analyses. And I think that needs to be continued as we progress into using these medications for longer periods of time, to ensure that we know the entirety of the risks and the benefits of them. So I would like to just continue to see this research being done and all these details flushed out.' – Benjamin Bert, MD

Why the size of your neck could reveal hidden risks to your heart health
Why the size of your neck could reveal hidden risks to your heart health

The Independent

time9 hours ago

  • The Independent

Why the size of your neck could reveal hidden risks to your heart health

The size of a person's neck relative to their body can predict various health markers, studies have found. Research has shown that the size of a person's neck in proportion to their body can be an indicator of health, linked to factors such as cardiovascular risk, nutritional status, and even the likelihood of death. Doctors are increasingly looking beyond body mass index (BMI) and waist size to better understand how fat distribution in the body affects health. One area that has become increasingly studied is neck circumference, which can act as a simple measure of upper-body fat. Research suggests that people with a larger neck size may be more likely to develop cardiovascular problems. Scientists believe this could be because fat stored in the upper body releases more fatty acids into the bloodstream compared with fat stored lower down, placing greater strain on the heart. Findings from the long-running Framingham Heart Study and other research projects have linked a thicker neck with higher rates of diabetes, insulin resistance and high blood pressure – all of which are key risk factors for atrial fibrillation (Afib), a common heart rhythm disorder. Importantly, these associations remain even when BMI and waist measurements are taken into account, suggesting that neck size provides unique insights into health risks. The NHS says Afib is a type of heart rhythm problem where your heartbeat is not steady. The main symptoms of atrial fibrillation include an irregular heartbeat, heart palpitations, and a heartbeat faster than 100 beats per minute. A large neck has also been linked to a higher chance of obstructive sleep apnoea, a condition where breathing repeatedly stops and starts during sleep, which itself raises the likelihood of Afib. A 2022 study in the Journal of the American Heart Association examined the data from around 4,000 people in the Framingham Heart Study. The researchers found that men with a neck size of 17 inches or more, and women with 14 inches or more, faced a higher risk of developing Afib compared to those with smaller measurements. The authors noted that 'individuals with high neck circumference had increased risk of incident Afib compared with those with low neck circumference,' and that this was true even after adjusting for BMI, waist circumference, height and weight. The association was strongest among participants with obesity, suggesting that neck size may be an especially important risk marker in this group. 'Our findings indicate that neck circumference potentially may be used as an easily obtainable measure for assessing risk of incident Afib' the researchers concluded, calling for further studies to explore its role in prevention and treatment.

Natural compound found in popular hot drink could protect brain against Alzheimer's, study finds
Natural compound found in popular hot drink could protect brain against Alzheimer's, study finds

The Independent

time13 hours ago

  • The Independent

Natural compound found in popular hot drink could protect brain against Alzheimer's, study finds

Scientists have identified two natural compounds that could help reverse ageing in brain cells and remove harmful protein buildup, raising hopes for a non-drug approach to treat Alzheimer's disease. The research, published in the journal GeroScience, identifies two natural compounds, nicotinamide – a form of vitamin B3 – and an antioxidant found in green tea called epigallocatechin gallate, which help restore a key molecule that fuels energy production in brain cells. Researchers found that nerve cells treated with these compounds not only experienced reversal of age -related decline but also an enhanced ability to clear away amyloid protein clusters, a hallmark feature of Alzheimer 's. 'As people age, their brains show a decline in neuronal energy levels, which limits the ability to remove unwanted proteins and damaged components,' said Gregory Brewer, lead author of the study. 'We found that restoring energy levels helps neurons regain this critical cleanup function,' Dr Brewer said. Researchers used a fluorescent molecule to track live guanosine triphosphate levels in neurons from aged mice showing signs of Alzheimer 's. Scientists found that the levels of energy-rich molecules GTP declined with age – particularly in the cells' mitochondria – leading to impaired elimination of cells with damaged components in a process called autophagy. While it is known that autophagy, the cell's natural clean-up process, plays a key role in maintaining the health of tissues and organs, what part of ageing causes impairment in this process remains elusive. When aged nerve cells were treated for just 24 hours with the study molecules nicotinamide and epigallocatechin gallate, the GTP levels were restored to levels typically seen in younger cells. 'Our results reveal age and AD-related neuronal GTP energy deficits that impair autophagy,' scientists wrote. The molecules also improved energy metabolism within these cells, as well as efficient clearance of amyloid beta clusters. 'By supplementing the brain's energy systems with compounds that are already available as dietary supplements, we may have a new path toward treating age-related cognitive decline and Alzheimer's disease,' Dr Brewer said. 'This study highlights GTP as a previously under-appreciated energy source driving vital brain functions,' he added. Researchers cautioned that more studies are required to find the best way to administer the compounds as treatment. A recent study also showed that nicotinamide was not very effective when taken orally due to its inactivation in the bloodstream. However, the findings point to promising strategies to rescue neurons in the brain's hippocampus from energy deficits related to ageing and Alzheimer's disease, researchers say.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store